Subclinical proximal tubulopathy in hepatitis B: The roles of nucleot(s)ide analogue treatment and the hepatitis B virus

Paul Carrier; Marilyne Debette-Gratien; Anais Labrunie; Sophie Alain; Marianne Maynard; Nathalie Ganne-Carrie; Eric Nguyen-Khac; Pauline Pinet; Victor de Ledinghen; Christophe Renou; Philippe Mathurin; Claire Vanlemmens; Vincent Di Martino; Anne Gervais; Juliette Foucher; Fouchard-Hubert Isabelle; Julien Vergniol; Isabelle Hourmand-Ollivier; Daniel Cohen; Xavier Duval; Thierry Poynard; Marc Bardou; Armand Abergel; Manh-Thong Dao; Thierry Thevenot; Jean-Baptiste Hiriart; Valerie Canva; Guillaume Lassailly; Christine Aurieres; Nathalie Boyer; Dominique Thabut; Pierre-Henri Bernard; Matthieu Schnee; Dominique Larrey; Bertrand Hanslik; Severine Hommel; Jeremie Jacques; Veronique Loustaud-Ratti; Anais Brayette; Marie Essig

doi:10.4254/wjh.v12.i12.1326

Article dans une revue

Subclinical proximal tubulopathy in hepatitis B: The roles of nucleot(s)ide analogue treatment and the hepatitis B virus

Paul Carrier ^{1, 2} Marilyne Debette-Gratien ^{1, 2} Anais Labrunie ^{3, 4} Sophie Alain ⁵ Marianne Maynard ⁶ Nathalie Ganne-Carrie ⁷ Eric Nguyen-Khac ⁸ Pauline Pinet ⁹ Victor de Ledinghen ¹⁰ Christophe Renou ¹¹ Philippe Mathurin ¹² Claire Vanlemmens ¹³ Vincent Di Martino ¹³ Anne Gervais ¹⁴ Juliette Foucher ¹⁵ Fouchard-Hubert Isabelle ¹⁰ Julien Vergniol ¹⁶ Isabelle Hourmand-Ollivier ¹⁷ Daniel Cohen ^{18, 19} Xavier Duval ^{20, 21} Thierry Poynard ²² Marc Bardou ²³ Armand Abergel ²⁴ Manh-Thong Dao ²⁵ Thierry Thevenot ²⁶ Jean-Baptiste Hiriart ²⁷ Valerie Canva ²⁸ Guillaume Lassailly ²⁹ Christine Aurieres ³⁰ Nathalie Boyer ^{31, 32, 33} Dominique Thabut ³⁴ Pierre-Henri Bernard ³⁵ Matthieu Schnee ³⁶ Dominique Larrey ^{37, 38} Bertrand Hanslik ³⁹ Severine Hommel ⁴⁰ Jeremie Jacques ¹ Veronique Loustaud-Ratti ⁴¹ Anais Brayette ¹ Marie Essig ^{42, 43}

1 Service d'Hépato-Gastro-Entérologie et Nutrition [CHU Limoges]

2 Pôle Universitaire d’Addictologie en Limousin

3 NET - Neuroépidémiologie Tropicale

4 CEBIMER - Plate forme de bioinformatique et biostatistique

5 RESINFIT - Anti-infectieux : supports moléculaires des résistances et innovations thérapeutiques

6 Hôpital de la Croix-Rousse [CHU - HCL]

7 FunGeST - Génomique fonctionnelle des tumeurs solides = Functional Genomics of Solid Tumors [CRC]

CRC (UMR_S_1138 / U1138) - Centre de Recherche des Cordeliers

8 GRAP - Groupe de Recherche sur l'alcool et les pharmacodépendances - UMR INSERM_S 1247

9 Service des Maladies infectieuses et tropicales [CHU Limoges]

10 CHU Angers - Centre Hospitalier Universitaire d'Angers

11 Hepatology

12 Physiopathologie des Maladies Inflammatoires de l'Intestin

13 CHRU Besançon - Centre Hospitalier Régional Universitaire de Besançon

14 Services de Maladies Infectieuses et Tropicales [CHU Bichat]

15 CHU Bordeaux [Bordeaux]

16 Service d'Hépato-gastro-entérologie et oncologie digestive (CHU de Bordeaux)

17 Service d'Hépato-Gastro-Enterologie et Nutrition [CHU Caen]

18 PSE - Paris School of Economics

19 PJSE - Paris Jourdan Sciences Economiques

20 AP-HP - Hôpital Bichat - Claude Bernard [Paris]

21 U738 / UMR_S738 - Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques

22 Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases [IHU ICAN]

23 CIC-P803 - Centre d'Investigation Clinique 1432 (Dijon) - Module Plurithématique : Périnatalité Cancérologie Handicap et Ophtalmologie

24 IP - Institut Pascal

25 UNICAEN - Université de Caen Normandie

26 Service d'Hépatologie [CHRU Besançon]

27 Hôpital Haut-Lévêque [CHU Bordeaux]

28 Hôpital Claude Huriez [Lille]

29 INFINITE (Ex-Liric) - Institute for Translational Research in Inflammation - U 1286

30 Service d’Hépatologie [Hôpital Beaujon]

31 UPC - Université Paris Cité

32 CRI (UMR_S_1149 / ERL_8252 / U1149) - Centre de recherche sur l'Inflammation

33 Hôpital Beaujon [AP-HP]

34 Service d'Hépato-Gastro-Entérologie [CHU Pitié-Salpêtrière]

35 Service d'Hépato-Gastro-Entérologie

36 Service de gastroentérologie (CHD Vendee - Hopital Les Oudairies, La Roche Sur Yon)

37 Hôpital Saint-Éloi [Montpellier]

38 Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB)

39 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]

40 Service d'Hépato-Gastroentérologie [CHU Rouen]

41 IPPRITT - Ciblage individuel et prévention des risques de traitements immunosupresseurs et de la transplantation

42 U1018 (Équipe 5) - Épidémiologie et recherches translationnelles sur les maladies rénales et cardiovasculaires (EPREC)

CESP - Centre de recherche en épidémiologie et santé des populations

43 Service Néphrologie/Dialyse [AP-HP Ambroise-Paré]

Abstract : BACKGROUND The recommended monitoring tools for evaluating nucleot(s)ide analogue renal toxicity, such as estimated glomerular filtration rate (eGFR) and phosphatemia, are late markers of proximal tubulopathy. Multiple early markers are available, but no consensus exists on their use. AIM To determine the 24 mo prevalence of subclinical proximal tubulopathy (SPT), as defined with early biomarkers, in treated vs untreated hepatitis B virus (HBV)-monoinfected patients. METHODS A prospective, non-randomized, multicenter study of HBV-monoinfected patients with a low number of renal comorbidities was conducted. The patients were separated into three groups: Naive, starting entecavir (ETV) treatment, or starting tenofovir disoproxil (TDF) treatment. Data on the early markers of SPT, the eGFR and phosphatemia, were collected quarterly. SPT was defined as a maximal tubular reabsorption of phosphate/eGFR below 0.8 mmoL/L and/or uric acid fractional excretion above 10%. The prevalence and cumulative incidence of SPT at month 24 (M24) were calculated. Quantitative data were analyzed using analyses of variance or Kruskal-Wallis tests, whereas chi-squared or Fisher's exact tests were used to analyze qualitative data. Multivariate analyses were used to adjust for any potential confounding factors. RESULTS Of the 196 patients analyzed, 138 (84 naive, 28 starting ETV, and 26 starting TDF) had no SPT at inclusion. At M24, the prevalence of SPT was not statistically different between naive and either treated group (21.1% vs 30.7%, P < 0.42 and 50.0% vs 30.7%, P = 0.32 for ETV and TDF, respectively); no patient had an eGFR lower than 50 mL/min/1.73 m(2) or phosphatemia less than 0.48 mmoL/L. In the multivariate analysis, no explanatory variables were identified after adjustment. The cumulative incidence of SPT over 24 mo (25.5%, 13.3%, and 52.9% in the naive, ETV, and TDF groups, respectively) tended to be higher in the TDF group vs the naive group (hazard ratio: 2.283, P = 0.05). SPT-free survival at M24 was 57.6%, 68.8%, and 23.5% for the naive, ETV, and TDF groups, respectively. The median survival time without SPT, evaluated only in the TDF group, was 5.9 mo. CONCLUSION The prevalence and incidence of SPT was higher in TDF-treated patients compared to naive patients. SPT in the naive population suggests that HBV can induce renal tubular toxicity.

Keywords : Hepatitis B virus Proximal tubulopathy Biomarkers Renal insufficiency Nucleoside analogues

Type de document :

Article dans une revue

Domaine :

Sciences du Vivant [q-bio]

Liste complète des métadonnées

https://hal-u-picardie.archives-ouvertes.fr/hal-03590856
Contributeur : Louise Dessaivre Connectez-vous pour contacter le contributeur
Soumis le : lundi 28 février 2022 - 11:11:02
Dernière modification le : jeudi 12 mai 2022 - 08:04:03

Subclinical proximal tubulopathy in hepatitis B: The roles of nucleot(s)ide analogue treatment and the hepatitis B virus

Licence

Lien texte intégral

Identifiants

Collections

Citation

Exporter

Métriques

18

Subclinical proximal tubulopathy in hepatitis B: The roles of nucleot(s)ide analogue treatment and the hepatitis B virus

Licence

Lien texte intégral

Identifiants

Collections

Citation

Exporter

Partager

Métriques

18